AGTC - Applied Genetic Technologies Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Applied Genetic Technologies Corporation

14193 NW 119th Terrace
Suite 10
Alachua, FL 32615
United States

Full Time Employees85

Key Executives

NameTitlePayExercisedYear Born
Ms. Susan B. WasherPres, CEO & Director777.27kN/A1961
Dr. Mark S. ShearmanChief Scientific Officer538.93kN/A1960
Dr. Matthew FeinsodExec. VP of Global Strategy & Devel.711.2kN/A1971
Dr. Nicholas MuzyczkaCo-FounderN/AN/AN/A
Dr. Barry J. ByrneCo-FounderN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. It focuses in the field of ophthalmology, with clinical programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM), as well as a preclinical program in optogenetics. The company also has initiated preclinical programs in adrenoleukodystrophy and otology indications. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.

Corporate Governance

Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.